

### Management of Non-Neutropenic Fever in Pediatric Oncology Patients

December 9, 2022

Alexandra Satty, MD Jessica Steifel, MD

#### No conflicts of interest to disclose

#### 3

Fever is a common complication in pediatric oncology patients, but is not consistently defined

- Temperature ≥38.0°C
   OR
- Temperature ≥38.0°C for over an hour or ≥38.3°C
   OR
- Temperature ≥38.0°C for over an hour or ≥38.5°C



Paganini *et al.*, 2000 Esbenshade *et al.*, 2015 Wu *et al.*, 2019 Freifeld *et al.*, 2011 Fever may be caused by many etiologies, the most common of which is infection

- Infection
  - $\circ$  Bacterial
  - $\circ$  Viral
  - $\circ$  Fungal
- Inflammation
- Transfusion reaction
- Hemophagocytic lymphohistiocytosis (HLH)
- Medication-induced: antibiotics, chemotherapy
- Underlying malignancy
- Dysautonomia

Serious bacterial infection occurs more commonly in pediatric oncology patients, and can lead to increased morbidity and mortality

Pediatric oncology patients are at high risk for serious bacterial infections due to **underlying diagnosis** and **treatment-related side effects** 

Rates of bacteremia in pediatric oncology patients presenting with fever estimated at:

- Neutropenic fever: 10 16.1%
- Non-neutropenic fever: 3.1 10.9%

Risk factors for serious bacterial infections:

- Presence of indwelling central catheter
- Quantitative or functional neutropenia
- Immune suppression
- Mucosal barrier breakdown due to mucositis

## Considerations in the evaluation of pediatric oncology patients with fever

- Does the patient have an indwelling central venous catheter?
- Is patient likely to be severely neutropenic?
  - What treatment regimen is patient receiving
  - What day of cycle are they today?
  - What was their last ANC?
  - What was their ANC at this time in their last cycle?
- Does patient have other risk factors for bacteremia?
- Is there another likely explanation for etiology of fever?

While management of fever with severe neutropenia is fairly standardized, management of non-neutropenic fever varies widely

- No consensus recommendations for management of <u>fever</u> in patients with <u>central venous catheters (CVC)</u> who are <u>not severely neutropenic</u>
- ASPHO survey (2003): 55-69% of providers reported administering antibiotics empirically to patients with non-neutropenic fever
- Small single institution studies suggest safety of withholding empiric antibiotics:
  - Stanford: 2.5% received empiric antibiotics (all admitted due to ill appearance) 6.1% rate of bacteremia
  - Northwestern: 17.3% empiric antibiotics 3.4% bacteremia

Ali *et al.*, 2015 Salzer *et al.*, 2003 Wu *et al.*, 2019 Clinical risk-prediction models are being developed to predict risk of serious bacterial infection in patients with non-neutropenic fever

Clinical risk-prediction model (EsVan) -

- Patient location at presentation
- Type of CVC
- Presence of hypotension
- Presence of shaking chills
- Diagnosis of ALL vs. other
- History of HSCT
- Presence of URI symptoms

- Exposure to medication(s) known to cause fever within prior 24h
  - Cytarabine, anti-GD2 Ab, ATG
- Age
- Maximum fever
- ANC
- Absolute monocyte count (AMC)

# Clinical risk-prediction models are being developed to predict risk of serious bacterial infection in patients with non-neutropenic fever

-	$\rightarrow$	С	企		cqs.app.vumc.org/shiny/RiskPrediction/	1
---	---------------	---	---	--	----------------------------------------	---

OneMSK Home - O...

G 🖻 🕁


Risk prediction model for the diagnosis of blood stream infection in febrile pediatric oncology patients without severe neutropenia


Where was the patient located at presentation?	Did the patient have Acute lymphoblastic leukemia?	What is the patient's age in years? [0 - 25]
<ul> <li>In patient</li> <li>Out patient</li> <li>What type of central line did the subject have</li> </ul>	<ul> <li>No</li> <li>Did the patient have a history of stem cell transplant?</li> <li>Yes</li> </ul>	Body temperature unit Please select
at presentation? <ul> <li>Port-A-Cath</li> <li>PICC line</li> </ul>	○ No Did the patient have upper respiratory symptoms?	What was the Absolute Neutrophil Count (ANC)? [cells/uL, 500 - 45000]
<ul> <li>Hickman line</li> <li>Was Hypotension present?</li> </ul>	<ul> <li>○ Yes</li> <li>○ No</li> </ul>	Was the absolute monocyte count available at the time of presentation?
<ul><li>○ Yes</li><li>○ No</li></ul>	Did the patient have drug exposure to cytarabine, ATG, or Anti-GD2 within 24 hours of presentation?	
Did the patient have shaking chills or rigors? <ul> <li>Yes</li> <li>No</li> </ul>	⊖ No	Generate Prediction based on ESVAN2 Reset

 $\rightarrow$  Predicted risk of bloodstream infection


Esbenshade et al., 2020

### Decreasing empiric antibiotic administration: a single center quality improvement initiative





### Decreasing empiric antibiotic administration: a single center quality improvement initiative



Decreasing empiric antibiotic administration: a single center quality improvement initiative

Bacteremia:

Pre-intervention 2.1%

Event:

**5.1%** (11/217)

Serious adverse event:

**0%** (0/217)

#### Conclusions

(1) Fever is a common complication in pediatric oncology

- (2) Pediatric oncology patients have many risk factors for serious bacterial infections
- (3) Empiric antibiotics may be safely withheld in selected patients with nonneutropenic fever assessed to be at low risk of bacteremia

#### Thank you!

Zahra Hudda Madhavi Lakkaraja Gabriela Llaurador Mauricio Rendon Joshua Resa Audrey Mauguen Julia Glade Bender Maria Luisa Sulis

Farid Boulad Jim Killinger Esther Babady Ellen Basu **Rachel Bright** Cynthia Chu **Rachel Corke** Debbie Diotallevi

Jennifer Levine Shakeel Modak Jane Peterson Susan Seo Anthony Trimarchi MSK Kids MDs, APPs, RNs Patients and families